Bessemer Group
PCVX icon

Bessemer Group’s Vaxcyte PCVX Stock Holding History

Bessemer Group’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9K Buy
162
+39
+32% +$2.12K ﹤0.01% 2176
2026
Q1 		$7K Hold
123
– – ﹤0.01% 2179
2025
Q4 		$6K Sell
123
-355
-74% -$15.9K ﹤0.01% 2228
2025
Q3 		$17K Buy
478
+273
+133% +$9.04K ﹤0.01% 1760
2025
Q2 		$7K Buy
205
+90
+78% +$2.95K ﹤0.01% 1937
2025
Q1 		$4K Sell
115
-147
-56% -$11.8K ﹤0.01% 2103
2024
Q4 		$21K Sell
262
-498
-66% -$49.5K ﹤0.01% 1508
2024
Q3 		$86K Buy
760
+141
+23% +$12.7K ﹤0.01% 1305
2024
Q2 		$47K Buy
+619
New +$42.1K ﹤0.01% 1286

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Bessemer Group's PCVX Position: Q2 2026 in Review

Bessemer Group increased its Vaxcyte (PCVX) stake by 32% in Q2 2026, buying an estimated $2.12K and bringing the position to 162 shares worth $9K. The position accounts for ﹤0.01% of the portfolio, ranked #2176.

Bessemer Group first reported a position in PCVX in Q2 2024 and has held it in 9 quarters since. The position peaked at $86K in Q3 2024. 332 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Bessemer Group held 162 shares of Vaxcyte worth $9K as of Q2 2026.
  • Bessemer Group bought 39 Vaxcyte shares in Q2 2026, an estimated $2.12K.
  • Vaxcyte made up ﹤0.01% of Bessemer Group's portfolio in Q2 2026, its #2176 holding.
  • Bessemer Group first reported a position in Vaxcyte in Q2 2024 and has held it in 9 quarters since.
  • Bessemer Group's Vaxcyte position peaked at $86K in Q3 2024.
  • 332 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Bessemer Group's 13F filing for Q2 2026, filed 12 Aug 2026.